Related Experiment Video
Updated: Jun 12, 2025

05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
17.8K
CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir
Camilla Muccini1, Nicola Gianotti1, Riccardo Lolatto1
1Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute.
AIDS (London, England)
|September 26, 2024
Abstract:
Our study assessed the CD4+/CD8+ ratio in people with HIV (PWH) switching from a second-generation integrase inhibitor regimen to long-acting cabotegravir (CAB) and rilpivirine (RPV). Over one year, we observed a significant improvement in the CD4+/CD8+ ratio; In addition, our data showed that time spent in CAB+RPV was significantly associated with an increased CD4+/CD8+ ratio. These findings suggest that long-acting therapy may enhance immune recovery, also in treatment-experienced PWH.

